预约演示
更新于：2026-07-22
Limaprost
利马前列素
更新于：2026-07-22
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C58H96O35 |
InChIKeyYBJQXILILWHFAT-UYXACNQFSA-N |
CAS号88852-12-4 |
关联
13
项与 利马前列素 相关的临床试验ChiCTR2400092866
A Randomized Controlled Trial to Evaluate the Efficacy and Safety of Limaprost Tablets for Patients with Residual Paresthesia after Lumbar Fusion Surgery for Degenerative Lumbar Spinal Stenosis
KCT0008042
Comparison of the therapeutic effect of limaprost and pregabalin on upper limb sensory neuropathy in patients with cervical radiculopathy, among patients with acquired lumbar spinal stenosis.
JPRN-jRCTs031200282
Clinical effect of NTN tablets on lumbar spinal canal stenosis with low back pain
-Multicenter,Randomized,Active-control open-label trial-
100 项与 利马前列素 相关的临床结果
登录后查看更多信息
100 项与 利马前列素 相关的转化医学
登录后查看更多信息
100 项与 利马前列素 相关的专利（医药）
登录后查看更多信息
100
项与 利马前列素 相关的文献（医药）2026-02-01EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Use of pregabalin and limaprost in the conservative treatment of lumbar spinal stenosis: a systematic review of the current evidence
Review
作者: Colella, Filippo Emanuele ; Baricich, Alessio ; Hammond, Jordan ; El Choueiri, Jad ; Di Cosmo, Leonardo ; Centini, Francesca Romana ; Natale, Leonardo ; Zaed, Ismail ; Uralov, Daniel ; Pellicanò, Francesca ; Learmonth, Chiara
BACKGROUND AND OBJECTIVES:
Lumbar spinal stenosis (LSS) is a common degenerative condition and a leading cause of pain and disability in older patients. While conservative treatment options like limaprost, a prostaglandin E1 analog, and pregabalin, a neuropathic pain modulator, are increasingly used, their relative efficacy and safety remain unclear. This systematic review aims to evaluate the comparative efficacy of pregabalin and limaprost in managing pain, function, quality of life, and adverse events in LSS.
METHODS:
A systematic search was conducted following PRISMA guidelines. Searches were performed across PubMed, Embase, Scopus, and Cochrane for studies published between January 2000 and March 2025. Inclusion criteria focused on RCTs and cohort studies evaluating either drug in LSS patients.
RESULTS:
Nine studies (6 RCTs, 3 cohort studies) with a total of 860 participants were included. Two head-to-head trials found no significant differences between pregabalin and limaprost in improving pain, disability, or quality of life. Both agents were associated with significant within-group improvements. Pregabalin showed efficacy across outcomes when combined with NSAIDs but was consistently associated with a higher frequency of adverse events, primarily including dizziness and gastrointestinal disturbances, compared to limaprost. Limaprost demonstrated mixed results, with several studies reporting benefits primarily when combined with other agents instead of its monotherapy. Evidence on sleep quality outcomes was limited but suggests potential benefits for both drugs in this patient population.
CONCLUSION:
No agent demonstrated clear superiority in the treatment of LSS, though both pregabalin and limaprost showed significant within-group benefits. Pregabalin's greater side effect profile and cost may support preferential use of limaprost in LSS patients. Nevertheless, due to limited comparative trials and substantial heterogeneity in interventions and outcome measures, further high-quality studies are needed to elucidate this non-inferiority and inform clinical guidelines.
2026-01-01Global Spine Journal
The Patient-Reported Outcomes of Postoperative Prostaglandin E1 Derivative in Lumbar Spine Surgery: A Randomized, Double-Blind, Controlled Trial
Article
作者: Maruay Tanayavong ; Wicharn Yingsakmongkol ; Vit Kotheeranurak ; Stephen J. Kerr ; Weerasak Singhatanadgige ; Worawat Limthongkul ; Kritsada Puttasean
Study Design:
A Randomized, Double-Blind, Controlled Trial.
Objective:
Postoperative residual leg numbness is a common complication following decompressive and fusion lumbar spine surgery. Prostaglandin E1 derivatives, such as limaprost, have demonstrated efficacy in reducing leg numbness in non-surgical populations. However, evidence regarding the efficacy of limaprost in post-surgical patients remains limited. This randomized controlled trial aimed to compare patient-reported outcomes between postoperative limaprost and placebo treatment.
Methods:
Sixty patients diagnosed with degenerative lumbar spine disease and undergoing one or two levels of decompressive and fusion lumbar spine surgery were randomized to receive either postoperative limaprost or placebo for 6 months. Primary outcome evaluation was leg numbness severity, as assessed using the Visual Analog Scale (VAS). Secondary outcomes included tingling sensation, back pain, leg pain, the Oswestry Disability Index (ODI), and the EuroQol-5D (EQ-5D).
Results:
Baseline demographic characteristics and patient-reported outcomes were comparable between the two groups. Both groups exhibited significant reductions in leg numbness at all postoperative time points (
P
< 0.001). However, no significant difference in leg numbness scores was observed between limaprost and placebo groups (
P
= 0.5). Notably, patients in limaprost group exhibited significantly greater reductions in back pain compared to the placebo group over the entire follow-up period (
P
< 0.001). No clinically significant differences were observed between groups for other patient-reported outcomes.
Conclusion:
Postoperative limaprost did not result in a significant reduction in leg numbness compared to placebo. Nevertheless, limaprost may offer potential benefits in alleviating back pain following decompressive and fusion lumbar spine surgery.
2025-06-01World Neurosurgery
Letter to the Editor Regarding “Comparative Study on the Efficacy of Pregabalin versus Limaprost in Patients with Lumbar Spinal Stenosis: A Prospective, Randomized Controlled Trial”
Article
作者: Jelmoni, Alice Jacqueline Mariangela ; Di Cosmo, Leonardo ; Centini, Francesca Romana
100 项与 利马前列素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 腰椎管狭窄症 | 日本 | 1988-01-20 | |
| 血栓闭塞性血管炎 | 日本 | 1988-01-20 | |
| 血栓闭塞性血管炎 | 日本 | 1988-01-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 退行性腰椎管狭窄症 | 临床申请批准 | 中国 | 2024-11-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用